Cyclerion Therapeutics (CYCN) Competitors $2.49 +0.11 (+4.45%) Closing price 08/22/2025 03:58 PM EasternExtended Trading$2.52 +0.03 (+1.17%) As of 08/22/2025 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CYCN vs. CLSD, AKTX, MURA, SNYR, BTAI, MAAQ, DYAI, JATT, KZR, and TRIBShould you be buying Cyclerion Therapeutics stock or one of its competitors? The main competitors of Cyclerion Therapeutics include Clearside Biomedical (CLSD), Akari Therapeutics (AKTX), Mural Oncology (MURA), Synergy CHC (SNYR), BioXcel Therapeutics (BTAI), Mana Capital Acquisition (MAAQ), Dyadic International (DYAI), JATT Acquisition (JATT), Kezar Life Sciences (KZR), and Trinity Biotech (TRIB). These companies are all part of the "pharmaceutical products" industry. Cyclerion Therapeutics vs. Its Competitors Clearside Biomedical Akari Therapeutics Mural Oncology Synergy CHC BioXcel Therapeutics Mana Capital Acquisition Dyadic International JATT Acquisition Kezar Life Sciences Trinity Biotech Cyclerion Therapeutics (NASDAQ:CYCN) and Clearside Biomedical (NASDAQ:CLSD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership and media sentiment. Is CYCN or CLSD more profitable? Cyclerion Therapeutics has a net margin of -89.51% compared to Clearside Biomedical's net margin of -665.19%. Clearside Biomedical's return on equity of 0.00% beat Cyclerion Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cyclerion Therapeutics-89.51% -22.63% -20.65% Clearside Biomedical -665.19%N/A -124.15% Which has stronger earnings & valuation, CYCN or CLSD? Cyclerion Therapeutics has higher revenue and earnings than Clearside Biomedical. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than Clearside Biomedical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCyclerion Therapeutics$2M4.15-$3.06M-$0.74-3.36Clearside Biomedical$1.66M19.26-$34.35M-$0.37-1.10 Do analysts rate CYCN or CLSD? Clearside Biomedical has a consensus price target of $4.20, indicating a potential upside of 931.43%. Given Clearside Biomedical's stronger consensus rating and higher possible upside, analysts clearly believe Clearside Biomedical is more favorable than Cyclerion Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cyclerion Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Clearside Biomedical 0 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.17 Does the media prefer CYCN or CLSD? In the previous week, Cyclerion Therapeutics' average media sentiment score of 0.00 equaled Clearside Biomedical'saverage media sentiment score. Company Overall Sentiment Cyclerion Therapeutics Neutral Clearside Biomedical Neutral Which has more risk & volatility, CYCN or CLSD? Cyclerion Therapeutics has a beta of 1.68, meaning that its share price is 68% more volatile than the S&P 500. Comparatively, Clearside Biomedical has a beta of 2.08, meaning that its share price is 108% more volatile than the S&P 500. Do insiders and institutionals have more ownership in CYCN or CLSD? 75.6% of Cyclerion Therapeutics shares are owned by institutional investors. Comparatively, 18.8% of Clearside Biomedical shares are owned by institutional investors. 34.3% of Cyclerion Therapeutics shares are owned by insiders. Comparatively, 6.7% of Clearside Biomedical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryClearside Biomedical beats Cyclerion Therapeutics on 8 of the 14 factors compared between the two stocks. Get Cyclerion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYCN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CYCN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYCN vs. The Competition Export to ExcelMetricCyclerion TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.94M$3.11B$5.76B$9.60BDividend YieldN/A2.23%4.41%4.10%P/E Ratio-3.3620.8831.1026.04Price / Sales4.15348.66434.92103.40Price / CashN/A43.1937.7358.48Price / Book0.978.129.536.61Net Income-$3.06M-$54.72M$3.26B$265.56M7 Day Performance5.34%2.63%2.10%1.95%1 Month Performance-17.13%2.78%2.82%-0.37%1 Year Performance-19.02%11.01%30.56%19.02% Cyclerion Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYCNCyclerion Therapeutics1.5224 of 5 stars$2.49+4.5%N/A-4.4%$7.94M$2M-3.3630Short Interest ↓CLSDClearside Biomedical1.8693 of 5 stars$0.42-2.3%$4.20+909.6%-59.7%$32.66M$4.17M-1.1230AKTXAkari Therapeutics2.3551 of 5 stars$0.99-0.6%$5.00+403.0%-75.1%$31.98MN/A0.009MURAMural Oncology2.9807 of 5 stars$1.82-0.3%$12.00+561.2%-36.6%$31.44MN/A-0.21119SNYRSynergy CHC4.2728 of 5 stars$3.37-3.2%$10.00+196.7%N/A$30.98M$33.70M8.8740BTAIBioXcel Therapeutics4.5844 of 5 stars$5.12-9.8%$39.75+676.8%-52.3%$30.72M$2.27M-0.4090Short Interest ↓MAAQMana Capital AcquisitionN/A$3.63-9.8%N/A+727.6%$29.49MN/A0.001DYAIDyadic International3.3543 of 5 stars$0.800.0%$6.00+654.7%-38.0%$28.77M$3.49M-4.187Gap UpJATTJATT AcquisitionN/A$1.66-3.5%N/A-43.8%$28.64MN/A0.003Gap UpHigh Trading VolumeKZRKezar Life Sciences3.8615 of 5 stars$3.88+0.4%$9.00+132.3%-33.6%$28.37M$7M-0.4060TRIBTrinity Biotech1.4602 of 5 stars$1.63+3.5%N/A-29.6%$28.25M$61.56M-0.53480Upcoming EarningsGap Down Related Companies and Tools Related Companies CLSD Competitors AKTX Competitors MURA Competitors SNYR Competitors BTAI Competitors MAAQ Competitors DYAI Competitors JATT Competitors KZR Competitors TRIB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CYCN) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclerion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclerion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access